What question did this study set out to answer?

To assess whether trans-complementing a VSV-vectored SARS-CoV-2 spike vaccine with the native VSV glycoprotein overcomes injection-site receptor limitations and improves protective immune responses.

July 25, 2022npj VaccinesOpen Access

Optimized intramuscular immunization with VSV-vectored spike protein triggers a superior immune response to SARS-CoV-2

View Full Paper

Ask AI

Bookmark

Authors

ATAdriano Taddeo IVInês Berenguer Veiga CDChristelle Devisme

Discussion

Member takes

Overview

Preclinical study demonstrates that trans-complemented VSV-vectored vaccines elicit robust protective immunity in transgenic mice, highlighting an improved intramuscular delivery strategy.

Key Points

To assess whether trans-complementing a VSV-vectored SARS-CoV-2 spike vaccine with the native VSV glycoprotein overcomes injection-site receptor limitations and improves protective immune responses.
Immunized K18-hACE2 transgenic mice intramuscularly with either standard or VSV glycoprotein trans-complemented VSV-vectored spike vaccine candidates.
Quantified spike-specific neutralizing antibody titers and subsequently challenged animals intranasally with lethal doses of SARS-CoV-2-S D614G or the Delta variant to evaluate survival, viral dissemination to the brain, and lung pathology.
Unmodified intramuscular VSV-spike vector failed to stimulate protective immunity, whereas trans-complementation with the VSV glycoprotein stimulated high neutralizing antibody titers.
Trans-complemented vaccination provided full protection against lethal SARS-CoV-2-S D614G infection and partial protection against the Delta variant, completely preventing viral spread to the brain while incompletely controlling lung viral replication and pathology.

Cite This Study

Taddeo et al. (2022) studied this question.

synapsesocial.com/papers/6aa9408c15a756b5ce462ef3 https://doi.org/10.1038/s41541-022-00508-7

View Full Paper

Ask AI

Bookmark

July 25, 2022npj VaccinesOpen Access

Optimized intramuscular immunization with VSV-vectored spike protein triggers a superior immune response to SARS-CoV-2

View Full Paper

Ask AI

Bookmark

Authors

ATAdriano Taddeo IVInês Berenguer Veiga CDChristelle Devisme

Discussion

Member takes

Overview

Preclinical study demonstrates that trans-complemented VSV-vectored vaccines elicit robust protective immunity in transgenic mice, highlighting an improved intramuscular delivery strategy.

Key Points

To assess whether trans-complementing a VSV-vectored SARS-CoV-2 spike vaccine with the native VSV glycoprotein overcomes injection-site receptor limitations and improves protective immune responses.
Immunized K18-hACE2 transgenic mice intramuscularly with either standard or VSV glycoprotein trans-complemented VSV-vectored spike vaccine candidates.
Quantified spike-specific neutralizing antibody titers and subsequently challenged animals intranasally with lethal doses of SARS-CoV-2-S D614G or the Delta variant to evaluate survival, viral dissemination to the brain, and lung pathology.
Unmodified intramuscular VSV-spike vector failed to stimulate protective immunity, whereas trans-complementation with the VSV glycoprotein stimulated high neutralizing antibody titers.
Trans-complemented vaccination provided full protection against lethal SARS-CoV-2-S D614G infection and partial protection against the Delta variant, completely preventing viral spread to the brain while incompletely controlling lung viral replication and pathology.

Cite This Study

Taddeo et al. (2022) studied this question.

synapsesocial.com/papers/6aa9408c15a756b5ce462ef3 https://doi.org/10.1038/s41541-022-00508-7

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark